Limits...
Type 1 diabetes and autoimmunity.

Kawasaki E - Clin Pediatr Endocrinol (2014)

Bottom Line: In a combined analysis, 94% of Japanese patients with T1D can be defined as having type 1A diabetes.Furthermore, autoantibodies to ZnT8 and IA-2 are associated with childhood-onset and acute-onset patients.Thus, it is important to develop a diagnostic strategy for patients with type 1A diabetes in consideration of the age or mode of disease onset.

View Article: PubMed Central - PubMed

Affiliation: Department of Diabetes and Metabolism, Nagasaki Harbor Medical Center City Hospital, Nagasaki, Japan.

ABSTRACT
Type 1 diabetes (T1D) is an organ-specific autoimmune disease caused by the autoimmune response against pancreatic β cells. T1D is often complicated with other autoimmune diseases, and anti-islet autoantibodies precede the clinical onset of disease. The most common coexisting organ-specific autoimmune disease in patients with T1D is autoimmune thyroid disease, and its frequency is estimated at > 90% among patients with T1D and autoimmune diseases. The prevalence of anti-thyroid antibodies in children with T1D at disease onset is about 20% and is particularly common in girls. Furthermore, patients with anti-thyroid antibodies are 18 times more likely to develop thyroid disease than patients without anti-thyroid antibodies. Therefore, for early detection of autoimmune thyroid disease in children with T1D, measurement of anti-thyroid antibodies and TSH at T1D onset and in yearly intervals after the age of 12 yr is recommended. Anti-islet autoantibodies are predictive and diagnostic markers for T1D. The most frequently detected autoantibodies in Japanese patients are GAD autoantibodies (~80%) followed by IA-2 autoantibodies (~60%), insulin autoantibodies (~55%) and ZnT8 autoantibodies (~50%). In a combined analysis, 94% of Japanese patients with T1D can be defined as having type 1A diabetes. Furthermore, autoantibodies to ZnT8 and IA-2 are associated with childhood-onset and acute-onset patients. Thus, it is important to develop a diagnostic strategy for patients with type 1A diabetes in consideration of the age or mode of disease onset.

No MeSH data available.


Related in: MedlinePlus

Clinical utilities of anti-islet autoantibodies in patients with diabetes.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4219937&req=5

fig_004: Clinical utilities of anti-islet autoantibodies in patients with diabetes.

Mentions: The clinical utilities of anti-islet autoantibodies in patients with diabetes includediagnosis (type 1A or type 1B), prediction (progressor or non-progressor) and understandingof pathophysiology (insulitis-specific or nonspecific phenomenon) (Fig. 4Fig. 4.


Type 1 diabetes and autoimmunity.

Kawasaki E - Clin Pediatr Endocrinol (2014)

Clinical utilities of anti-islet autoantibodies in patients with diabetes.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4219937&req=5

fig_004: Clinical utilities of anti-islet autoantibodies in patients with diabetes.
Mentions: The clinical utilities of anti-islet autoantibodies in patients with diabetes includediagnosis (type 1A or type 1B), prediction (progressor or non-progressor) and understandingof pathophysiology (insulitis-specific or nonspecific phenomenon) (Fig. 4Fig. 4.

Bottom Line: In a combined analysis, 94% of Japanese patients with T1D can be defined as having type 1A diabetes.Furthermore, autoantibodies to ZnT8 and IA-2 are associated with childhood-onset and acute-onset patients.Thus, it is important to develop a diagnostic strategy for patients with type 1A diabetes in consideration of the age or mode of disease onset.

View Article: PubMed Central - PubMed

Affiliation: Department of Diabetes and Metabolism, Nagasaki Harbor Medical Center City Hospital, Nagasaki, Japan.

ABSTRACT
Type 1 diabetes (T1D) is an organ-specific autoimmune disease caused by the autoimmune response against pancreatic β cells. T1D is often complicated with other autoimmune diseases, and anti-islet autoantibodies precede the clinical onset of disease. The most common coexisting organ-specific autoimmune disease in patients with T1D is autoimmune thyroid disease, and its frequency is estimated at > 90% among patients with T1D and autoimmune diseases. The prevalence of anti-thyroid antibodies in children with T1D at disease onset is about 20% and is particularly common in girls. Furthermore, patients with anti-thyroid antibodies are 18 times more likely to develop thyroid disease than patients without anti-thyroid antibodies. Therefore, for early detection of autoimmune thyroid disease in children with T1D, measurement of anti-thyroid antibodies and TSH at T1D onset and in yearly intervals after the age of 12 yr is recommended. Anti-islet autoantibodies are predictive and diagnostic markers for T1D. The most frequently detected autoantibodies in Japanese patients are GAD autoantibodies (~80%) followed by IA-2 autoantibodies (~60%), insulin autoantibodies (~55%) and ZnT8 autoantibodies (~50%). In a combined analysis, 94% of Japanese patients with T1D can be defined as having type 1A diabetes. Furthermore, autoantibodies to ZnT8 and IA-2 are associated with childhood-onset and acute-onset patients. Thus, it is important to develop a diagnostic strategy for patients with type 1A diabetes in consideration of the age or mode of disease onset.

No MeSH data available.


Related in: MedlinePlus